RE:RE:RE:RE:RE:RE:RE:Wednesday Trading Yeah, it's critical Algernon uplist ASAP. Other than CSE-OTC being somewhat incompetent in understanding biotech valuatrions, the glaringv internal problem with algernon is it's timelines to get to data readouts. The CEO wants to consistently compare Algernon to Bellus Health in similar ways, but the absolutely most important way is an aggressive timeline to get to a data readout that Algernon lacks in spectacular fashion.
Bellus Health timeline of their second Phase II Chronic Cough clinical trial:
12/08/2020 BELLUS Health Announces First Patient Dosed in its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
09/13/2021 BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough
12/13/2021 Bellus Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the treatment of Refractory Chronic Cough.
Also see clinicaltrials.gov:
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 310 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized, Adaptive, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase 2b Study to Evaluate the Efficacy and Safety of Multiple Doses of BLU-5937 in Adult Participants With Refractory Chronic Cough |
| Actual Study Start Date : | December 7, 2020 |
| Actual Primary Completion Date : | October 21, 2021 |
| Actual Study Completion Date : | November 2, 2021 |
Take all the above into consideration of what Algernon has done thus far and the #! Thing of all things for a Biotech company is to execute a clinical trial strategy in the most expeditious way. Algernon does the opposite of that will tiny numbers of trial participants and years long to get to data readouts. Algernon's announcement of a stand-alone Chronic Cough clinical trial powered for statistical significance is long overdue is 2018. Yet, the company needs at least until Q2 2022 to design the clinical trial for a launch maybe in Q2 of Q3 2022. The blaring question is how long will it take for Algernon to get to a data readout? If I had to bet the farm, I'd say management will not design a clinical trial that will get to a data readout inside of a year like we know first hand can be done. BELLUS Health being proof of that. Yet, Algernon will design a clinical trial that will likely take at least 2 years to complete. Notwithstanding more excuses about a delay due to the pandemic. The same Pandemic that BELLUS Health masterfully navigated to expeditiously get to a data readout for their shareholders benefit. Time will tell and I tell you time has never been on the side of shareholders who are not on the inside.